Emblation Secures FDA 510(k) Clearance for Swift™ & SwiftPro™ Systems in Treatment of Common and Plantar Warts

Microwave therapy is proven to be the smarter, safer, less painful choice for wart treatment across the US and UK.

Emblation, the company redefining medical microwave technology, has received FDA 510(k) clearance for expanded indications of its Swift™ and SwiftPro™ Systems — officially confirming their use for the treatment of common and plantar warts.

Already trusted worldwide, Swift is now FDA-cleared for what clinicians have been reporting for years:

- Less painful

- Fewer side effects

- Faster resolution

The clinical study conducted confirmed that Swift patients experience less blistering, itching, tingling, discolouration and hypersensitivity and about half the pain compared to cryotherapy — all while achieving strong clinical outcomes.

Clinician-Backed. Patient-Preferred. FDA-Cleared.

Swift’s targeted microwave energy treats viral lesions without breaking the skin, offering a clean, non-invasive alternative to traditional destructive methods, such as cryotherapy, that can slow recovery and increase discomfort.

Ian Stevens, CEO of Emblation, said:

This FDA 510(k) clearance cements what thousands of clinicians already know — Swift delivers better outcomes with less pain than traditional methods, while being safer and more tolerable for patients. We’re thrilled to expand access to treatment for US patients and reaffirm its value across the UK and beyond.”

Dr Robert M. Conenello, Orangetown Podiatry, NY, commented:

“Swift should always be the first choice for treating common and plantar warts. We’ve relied on it for years, clearing cases in months instead of the years traditional treatments can take. This FDA recognition is incredibly well-deserved.”

About Emblation

Based in Stirling, UK, Emblation launched Swift™ in 2016. The system has now powered 500,000+ treatments worldwide, with more than 1,000 US clinicians already using the technology. Emblation’s microwave platforms have supported over 1 million tumour treatments globally, with ongoing development in oncology and dermatology.

Learn More

For more information visit swiftbyemblation.com